22 May 2007 Sydney, Australia: Biopharmaceutical company, Peptech Limited (ASX: PTD, AIM: PTDx) today announced the commencement of a Phase I trial of its lead compound PN0621, which marks the first administration to humans of a domain antibody derived product. The trial will determine the safety of the compound in up to 30 healthy volunteers and will take place at the St Vincent’s Hospital Clinical Trial Centre in Sydney.
